Seminars in Oncology
Volume 30, Issue 5 , Pages 678-688, October 2003

Endothelin receptor antagonists in the treatment of prostate cancer☆

  • Lance K Lassiter

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    • ,
  • Michael A Carducci

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    • Corresponding Author InformationAddress reprint requests to Michael A. Carducci, MD, Division of Medical Oncology, Room 1M-89, Cancer Research Building, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Supported by Abbott Laboratories. M.A.C. is a paid consultant for Abbott Laboratories. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.

PII: S0093-7754(03)00353-1

doi:10.1016/S0093-7754(03)00353-1

Seminars in Oncology
Volume 30, Issue 5 , Pages 678-688, October 2003

Article Tools